CardioActive Taurine, pills 500mg 60pcs

Composition

Composition per tablet

Active ingredient: taurine-500 mg.

Auxiliary components:

povidone-57.0 mg,

microcrystalline cellulose-18.0 mg,

croscarmellose sodium-17.2 mg,

calcium stearate-4.8 mg,

colloidal silicon dioxide-3.0 mg

Pharmacological action

Pharmacotherapy group:  a metabolic agent.

ATX code:  C01EB

Pharmacological properties

Pharmacodynamics

Taurine is a natural metabolic product of sulfur-containing amino acids:   cysteine, cysteamine, and methionine. Taurine has osmoregulatory and membrane-protective properties, has a positive effect on the phospholipid composition of cell membranes, and normalizes the exchange of calcium and potassium ions in cells.

Taurine has been shown to have the properties of an inhibitory neurotransmitter, it has an anti-stress effect, can regulate the release of gamma-aminobutyric acid (GABA), epinephrine, prolactin and other hormones, as well as regulate responses to them.

Participating in the synthesis of respiratory chain proteins in mitochondria, taurine regulates oxidative processes and exhibits antioxidant properties; it affects enzymes such as cytochromes involved in the metabolism of various xenobiotics.

Taurine improves metabolic processes in the heart, liver, and other organs and tissues. In chronic diffuse liver diseases, taurine increases blood flow and reduces the severity of cytolysis.

Treatment with Cardioactive® Taurine in cardiovascular insufficiency (CVI) leads to a decrease in congestion in the small and large circulatory circles: intracardiac diastolic pressure decreases, myocardial contractility increases (maximum rate of contraction and relaxation, contractility and relaxation indices).

The drug modestly reduces blood pressure (BP) in patients with arterial hypertension and practically does not affect the level of blood pressure in patients with cardiovascular insufficiency with low blood pressure.

Cardioactive® Taurine reduces the side effects that occur with an overdose of cardiac glycosides and slow calcium channel blockers; reduces the hepatotoxicity of antifungal drugs. Increases performance during heavy physical exertion.

In case of diabetes mellitus approximately 2 weeks after the start of taking Cardioactive® Taurine reduces the concentration of glucose in the blood. There was also a significant decrease in the concentration of triglycerides, to a lesser extent – the concentration of cholesterol, a decrease in the atherogenicity of plasma lipids. With prolonged use of the drug (about 6 months), an improvement in the microcirculatory blood flow of the eye was noted.

Pharmacokinetics

After a single oral dose of 500 mg of Cardioactive® Taurine, Active ingredient taurine is detected in the blood in 15-20 minutes, reaching a maximum in 1.5-2 hours. The drug is completely excreted in a day.

Indications

The drug is used in complex therapy:

• cardiovascular insufficiency of various etiologies;
• intoxication caused by taking cardiac glycosides;
• type 1 diabetes mellitus;
• type 2 diabetes mellitus, including those with moderate hypercholesterolemia.

Use during pregnancy and lactation

The use of Cardioactive®is not recommended Taurine during pregnancy and lactation due to the lack of sufficient experience of clinical use in this category of patients.

Contraindications

Severe heart failure in the stage of decompensation.

Hypersensitivity to the drug.

Cardioactive® Taurine is not recommended for use in children under 18 years of age due to insufficient data on efficacy and safety.

Side effects

Possible allergic reactions to the components of the drug.

Interaction

Cardioactive Taurine can be used with other medications.

Taurine enhances the inotropic effect of cardiac glycosides.

How to take, course of use and dosage

Consult your doctor before using the drug.

In case of heart failure, Cardioactive Taurine is taken orally at 250-500 mg (1/2-1 tablet) 2 times a day 20 minutes before meals, the course of treatment is 30 days.

The dose can be increased to 2-3 g (4-6 tablets) per day.

In case of intoxication with cardiac glycosides — at least 750 mg (1.5 tablets) per day.

For type 1 diabetes mellitus-500 mg (1 tablet) 2 times a day in combination with insulin therapy for 3-6 months.

For type 2 diabetes mellitus-500 mg (1 tablet) 2 times a day in combination with diet therapy or other hypoglycemic agents for oral use.

For type 2 diabetes mellitus, including those with moderate hypercholesterolemia-500 mg (1 tablet) 2 times a day.

Overdose

There are no data on overdose.

Special instructions

Use with caution in patients with severe renal impairment, when used concomitantly with cardiac glycosides, slow calcium channel blockers (BMCC).

Form of production

Pills.

Storage conditions

Store at a temperature not exceeding 25°C. Keep out of reach of children.

Shelf

life is 3 years.

Active ingredient

Taurine

Dosage form

Tablets